NR3C2 and cardiovascular disorder: (("empagliflozin" OR "dapagliflozin" OR "canagliflozin” OR "ertugliflozin” OR "Sodium-Glucose Transporter 2 Inhibitors”) OR ("spironolactone” OR "eplerenone” OR "finerenone” OR "Mineralocorticoid Receptor Antagonists”)) AND ("Heart Failure" OR "Cardiovascular Diseases”) AND (“randomized controlled trials” OR “randomised controlled trials”)